Research ExplorerPublicationsPharmacokinetics of ganciclovir during continuous venovenous...

Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients

Standard

Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. / Horvatits, Thomas; Kitzberger, Reinhard; Drolz, Andreas; Zauner, Christian; Jäger, Walter; Böhmdorfer, Michaela; Kraff, Stefanie; Fritsch, Achim; Thalhammer, Florian; Fuhrmann, Valentin; Schenk, Peter.

In: ANTIMICROB AGENTS CH, Vol. 58, No. 1, 01.01.2014, p. 94-101.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Horvatits, T, Kitzberger, R, Drolz, A, Zauner, C, Jäger, W, Böhmdorfer, M, Kraff, S, Fritsch, A, Thalhammer, F, Fuhrmann, V & Schenk, P 2014, 'Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients', ANTIMICROB AGENTS CH, vol. 58, no. 1, pp. 94-101. https://doi.org/10.1128/AAC.00892-13

APA

Horvatits, T., Kitzberger, R., Drolz, A., Zauner, C., Jäger, W., Böhmdorfer, M., Kraff, S., Fritsch, A., Thalhammer, F., Fuhrmann, V., & Schenk, P. (2014). Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ANTIMICROB AGENTS CH, 58(1), 94-101. https://doi.org/10.1128/AAC.00892-13

Vancouver

Horvatits T, Kitzberger R, Drolz A, Zauner C, Jäger W, Böhmdorfer M et al. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. ANTIMICROB AGENTS CH. 2014 Jan 1;58(1):94-101. https://doi.org/10.1128/AAC.00892-13

Bibtex

@article{6c5bff077e4f4dd99c0349866eab7fbb,
title = "Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients",
abstract = "Ganciclovir is an antiviral agent that is frequently used in critically ill patients with cytomegalovirus (CMV) infections. Continuous venovenous hemodiafiltration (CVVHDF) is a common extracorporeal renal replacement therapy in intensive care unit patients. The aim of this study was to investigate the pharmacokinetics of ganciclovir in anuric patients undergoing CVVHDF. Population pharmacokinetic analysis was performed for nine critically ill patients with proven or suspected CMV infection who were undergoing CVVHDF. All patients received a single dose of ganciclovir at 5 mg/kg of body weight intravenously. Serum and ultradiafiltrate concentrations were assessed by high-performance liquid chromatography, and these data were used for pharmacokinetic analysis. Mean peak and trough prefilter ganciclovir concentrations were 11.8 ± 3.5 mg/liter and 2.4 ± 0.7 mg/liter, respectively. The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined. Based on population pharmacokinetic simulations with respect to a target area under the curve (AUC) of 50 mg · h/liter and a trough level of 2 mg/liter, a ganciclovir dose of 2.5 mg/kg once daily seems to be adequate for anuric critically ill patients during CVVHDF.",
author = "Thomas Horvatits and Reinhard Kitzberger and Andreas Drolz and Christian Zauner and Walter J{\"a}ger and Michaela B{\"o}hmdorfer and Stefanie Kraff and Achim Fritsch and Florian Thalhammer and Valentin Fuhrmann and Peter Schenk",
year = "2014",
month = jan,
day = "1",
doi = "10.1128/AAC.00892-13",
language = "English",
volume = "58",
pages = "94--101",
journal = "ANTIMICROB AGENTS CH",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

RIS

TY - JOUR

T1 - Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients

AU - Horvatits, Thomas

AU - Kitzberger, Reinhard

AU - Drolz, Andreas

AU - Zauner, Christian

AU - Jäger, Walter

AU - Böhmdorfer, Michaela

AU - Kraff, Stefanie

AU - Fritsch, Achim

AU - Thalhammer, Florian

AU - Fuhrmann, Valentin

AU - Schenk, Peter

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Ganciclovir is an antiviral agent that is frequently used in critically ill patients with cytomegalovirus (CMV) infections. Continuous venovenous hemodiafiltration (CVVHDF) is a common extracorporeal renal replacement therapy in intensive care unit patients. The aim of this study was to investigate the pharmacokinetics of ganciclovir in anuric patients undergoing CVVHDF. Population pharmacokinetic analysis was performed for nine critically ill patients with proven or suspected CMV infection who were undergoing CVVHDF. All patients received a single dose of ganciclovir at 5 mg/kg of body weight intravenously. Serum and ultradiafiltrate concentrations were assessed by high-performance liquid chromatography, and these data were used for pharmacokinetic analysis. Mean peak and trough prefilter ganciclovir concentrations were 11.8 ± 3.5 mg/liter and 2.4 ± 0.7 mg/liter, respectively. The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined. Based on population pharmacokinetic simulations with respect to a target area under the curve (AUC) of 50 mg · h/liter and a trough level of 2 mg/liter, a ganciclovir dose of 2.5 mg/kg once daily seems to be adequate for anuric critically ill patients during CVVHDF.

AB - Ganciclovir is an antiviral agent that is frequently used in critically ill patients with cytomegalovirus (CMV) infections. Continuous venovenous hemodiafiltration (CVVHDF) is a common extracorporeal renal replacement therapy in intensive care unit patients. The aim of this study was to investigate the pharmacokinetics of ganciclovir in anuric patients undergoing CVVHDF. Population pharmacokinetic analysis was performed for nine critically ill patients with proven or suspected CMV infection who were undergoing CVVHDF. All patients received a single dose of ganciclovir at 5 mg/kg of body weight intravenously. Serum and ultradiafiltrate concentrations were assessed by high-performance liquid chromatography, and these data were used for pharmacokinetic analysis. Mean peak and trough prefilter ganciclovir concentrations were 11.8 ± 3.5 mg/liter and 2.4 ± 0.7 mg/liter, respectively. The pharmacokinetic parameters elimination half-life (24.2 ± 7.6 h), volume of distribution (81.2 ± 38.3 liters), sieving coefficient (0.76 ± 0.1), total clearance (2.7 ± 1.2 liters/h), and clearance of CVVHDF (1.5 ± 0.2 liters/h) were determined. Based on population pharmacokinetic simulations with respect to a target area under the curve (AUC) of 50 mg · h/liter and a trough level of 2 mg/liter, a ganciclovir dose of 2.5 mg/kg once daily seems to be adequate for anuric critically ill patients during CVVHDF.

U2 - 10.1128/AAC.00892-13

DO - 10.1128/AAC.00892-13

M3 - SCORING: Journal article

C2 - 24145543

VL - 58

SP - 94

EP - 101

JO - ANTIMICROB AGENTS CH

JF - ANTIMICROB AGENTS CH

SN - 0066-4804

IS - 1

ER -